Skip to main content
HeartCited

Potassium for High Blood Pressure (Hypertension)

B Good Evidence At least one randomized trial supports this, with mostly consistent results.

WHO conditional recommendation. Meta-analysis: systolic -3.49 mmHg. DASH diet (4,700 mg K/day) reduces systolic BP by 8-14 mmHg. Potassium-enriched salt substitutes reduced stroke risk by 14% in a 2022 Lancet study.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dpotassium\u0026condition\u003Dhigh\u002Dblood\u002Dpressure'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

The Bottom Line

WHO conditional recommendation. Meta-analysis: systolic -3.49 mmHg. DASH diet (4,700 mg K/day) reduces systolic BP by 8-14 mmHg. Potassium-enriched salt substitutes reduced stroke risk by 14% in a 2022 Lancet study.

Key Study Findings

Case Reports n=1
Pseudo-Hyperaldosteronism Arising from Licorice Cough Syrup Self-Ingestion: A Case Report.
Dose: Licorice cough syrup (glycyrrhiza glabra) vs: None Outcome: Hypokalemia, hypertension, metabolic alkalosis Effect: None None

Population: Single patient with licorice intoxication

Case Reports 13.0 weeks
A case report of Gitelman syndrome in children.
Dose: 3 g vs: None Outcome: pain reduction Effect: None None

Population: Hypokalemia

Case Reports n=1
Hypokalemia-induced rhabdomyolysis as the first symptom of primary aldosteronism: a case report and literature review.
Dose: None vs: None Outcome: None Effect: None None

Population: 65-year-old woman with primary aldosteronism

Meta-Analysis n=1258
Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials.
Dose: 25 mg/day (typical) vs: Placebo or standard care Outcome: All-cause mortality Effect: RR=0.42, P<0.0001 P<0.0001

Population: Dialysis-dependent ESRD patients

Case Reports n=1
Bilateral Adrenalectomy in a Patient With Refractory Primary Aldosteronism Due to Adrenal Hyperplasia.
Dose: None vs: None Outcome: None Effect: None None

Population: Patient with refractory primary aldosteronism

Other 8 weeks
Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative …
Dose: 150 g vs: None Outcome: whether the rats were acidotic, blood pH was … Effect: None None

Population: None

Key Statistics

22

Studies

1600

Participants

Positive

B

Grade

Referenced Papers

American family physician 2019 49 citations
Acta medica Iranica 2016 10 citations
Heart disease and … 1994
European heart journal 1985 23 citations
Drug intelligence & … 1981 7 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

supplements:
Typically 99 mg/dose (FDA limit per unit)
dashdiettarget:
4,700 mg/day
whorecommendation:
3,510 mg/day from food

Upper limit: No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

Dosages Studied in Research

Dosage Duration Effect N
Licorice cough syrup (glycyrrhiza glabra) -- Negative 1
3 g 13.0 weeks Mixed --
None -- Mixed 1
25 mg/day (typical) -- Positive 1258
None -- Mixed 1
150 g 8 weeks Neutral --
None -- Mixed --
20 mg -- Positive --

Best taken: With meals to reduce GI irritation; divide supplemental doses throughout the day

Safety & Side Effects

Reported Side Effects

  • Gastrointestinal irritation (nausea, vomiting, diarrhea)
  • Hyperkalemia risk in patients with renal impairment
  • Cardiac arrhythmias at excessively high serum levels

Known Interactions

  • ACE inhibitors (increased hyperkalemia risk)
  • ARBs (increased hyperkalemia risk)
  • Potassium-sparing diuretics (increased hyperkalemia risk)
  • NSAIDs (may increase potassium retention)

Tolerable upper intake: No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Potassium help with High Blood Pressure (Hypertension)?
Based on 22 studies with 1,600 participants, there is moderate evidence from clinical studies that Potassium may support High Blood Pressure (Hypertension) management. Our evidence grade is B (Good Evidence).
How much Potassium should I take for High Blood Pressure (Hypertension)?
Studies have used various dosages. A commonly studied range is Typically 99 mg/dose (FDA limit per unit). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Potassium?
Reported side effects may include Gastrointestinal irritation (nausea, vomiting, diarrhea), Hyperkalemia risk in patients with renal impairment, Cardiac arrhythmias at excessively high serum levels. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Potassium and High Blood Pressure (Hypertension)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 22 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.

References

  1. [1] Chien-Chun Liao et al.. Reports (MDPI). 2024. Pseudo-Hyperaldosteronism Arising from Licorice Cough Syrup Self-Ingestion: A Case Report. doi:10.3390/reports7040085 PubMed
  2. [2] Jing Ying et al.. Medicine (Baltimore). 2023. A case report of Gitelman syndrome in children. doi:10.1097/MD.0000000000033509 PubMed
  3. [3] Jing Liu et al.. Front Med (Lausanne). 2022. Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials. doi:10.3389/fmed.2022.828189 PubMed
  4. [4] Rongfeng Han et al.. Ann Palliat Med. 2022. Hypokalemia-induced rhabdomyolysis as the first symptom of primary aldosteronism: a case report and literature review. doi:10.21037/apm-21-3010 PubMed
  5. [5] Luis Marín-Martínez et al.. Cureus. 2022. Bilateral Adrenalectomy in a Patient With Refractory Primary Aldosteronism Due to Adrenal Hyperplasia. doi:10.7759/cureus.24267 PubMed
  6. [6] Dinesh Aryal et al.. Antioxidants (Basel). 2020. Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative Stress. doi:10.3390/antiox10010002 PubMed
  7. [7] Neetika Garg et al.. Clin Transplant. 2020. Prevalence of primary aldosteronism in hypertensive kidney transplant recipients: A cross-sectional study. doi:10.1111/ctr.13999 PubMed
  8. [8] Mary Carpenter et al.. Am Fam Physician. 2019. Clinically Relevant Drug-Drug Interactions in Primary Care. PubMed
  9. [9] Betty S Chan et al.. Clin Toxicol (Phila). 2016. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). doi:10.1080/15563650.2016.1175620 PubMed
  10. [10] Sedighe Moradi et al.. Acta Med Iran. 2016. A Woman with Normotensive Primary Hyperaldosteronism. PubMed
  11. [11] Alfredo Rossi et al.. Recent Pat Inflamm Allergy Drug Discov. 2012. Minoxidil use in dermatology, side effects and recent patents. doi:10.2174/187221312800166859 PubMed
  12. [12] Pernelle Noize et al.. Pharmacoepidemiol Drug Saf. 2011. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. doi:10.1002/pds.2128 PubMed
  13. [13] Deepani Rathnayake et al.. Dermatol Clin. 2010. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. doi:10.1016/j.det.2010.03.011 PubMed
  14. [14] Y Jammes et al.. J Intern Med. 2005. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. doi:10.1111/j.1365-2796.2005.01452.x PubMed
  15. [15] T Rickman et al.. Am J Kidney Dis. 2001. Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma. doi:10.1016/s0272-6386(01)80134-7 PubMed
  16. [16] E Bourke et al.. Heart Dis Stroke. 1994. Prevention of hypokalemia caused by diuretics. PubMed
  17. [17] T Dyckner et al.. Eur J Clin Pharmacol. 1986. Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial … doi:10.1007/BF00542411 PubMed
  18. [18] D L Kuchar et al.. Eur Heart J. 1985. High dose furosemide in refractory cardiac failure. doi:10.1093/oxfordjournals.eurheartj.a061793 PubMed
  19. [19] H L Macfie et al.. Drug Intell Clin Pharm. 1981. New drug evaluations amiloride (Midamor, Merck, Sharp and Dohme). doi:10.1177/106002808101500202 PubMed
  20. [20] G Lemieux et al.. Can Med Assoc J. 1980. Hypokalemia during the treatment of arterial hypertension with diuretics. PubMed
  21. [21] G Nuki et al.. Ann Rheum Dis. 1975. Potassium metabolism in patients with rheumatoid arthritis. Effects of treatment with depot tetracosactrin, spironolactone, and oral supplements of potassium chloride. doi:10.1136/ard.34.6.506 PubMed

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.